• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi.

作者信息

Zamprogna Giulia, Frustaci Anna Maria, Travi Giovanna, Borella Chiara, Reda Gianluigi, Motta Marina, Deodato Marina, Bossi Elisa, Mattiello Veronica, Ferrari Maria Beatrice, Cotilli Giulia, Gambacorti-Passerini Carlo, Cairoli Roberto, Puoti Massimo, Tedeschi Alessandra

机构信息

Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.

Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.

出版信息

Hemasphere. 2023 May 4;7(5):e880. doi: 10.1097/HS9.0000000000000880. eCollection 2023 May.

DOI:10.1097/HS9.0000000000000880
PMID:37153871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10162789/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2ab/10162789/14308665b8cc/hs9-7-e880-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2ab/10162789/14308665b8cc/hs9-7-e880-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2ab/10162789/14308665b8cc/hs9-7-e880-g001.jpg

相似文献

1
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi.替沙格韦单抗/西加韦单抗对接受布鲁顿酪氨酸激酶抑制剂治疗的淋巴增殖性疾病患者的暴露前预防
Hemasphere. 2023 May 4;7(5):e880. doi: 10.1097/HS9.0000000000000880. eCollection 2023 May.
2
Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.替沙格韦单抗/西加韦单抗用于暴露前预防，可降低奥密克戎变异株流行期间接受疫苗接种的实体器官移植受者突破性感染的风险。
Am J Transplant. 2022 Dec;22(12):3130-3136. doi: 10.1111/ajt.17128. Epub 2022 Jul 1.
3
Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis.替沙格韦单抗-西加韦单抗作为新型冠状病毒肺炎暴露前预防的疗效和安全性：一项系统评价和荟萃分析
Rev Med Virol. 2023 Mar;33(2):e2420. doi: 10.1002/rmv.2420. Epub 2023 Jan 8.
4
[Pharmacoeconomic evaluation of the tixagevimab and cilgavimab combination using for pre-exposure prophylaxis of COVID-19].替沙格韦单抗和西加韦单抗联合用于新型冠状病毒肺炎暴露前预防的药物经济学评价
Ter Arkh. 2023 Feb 24;95(1):66-77. doi: 10.26442/00403660.2023.01.202065.
5
Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.替沙格韦单抗/西加韦单抗用于 COVID-19 的预防和治疗：综述。
Expert Rev Anti Infect Ther. 2022 Dec;20(12):1517-1527. doi: 10.1080/14787210.2022.2134118. Epub 2022 Oct 27.
6
Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.SARS-CoV-2 奥密克戎亚变种在 COVID-19 免疫功能低下患者中的基因和表型分析，这些患者在接受 tixagevimab-cilgavimab 预防治疗后。
J Clin Virol. 2023 Mar;160:105382. doi: 10.1016/j.jcv.2023.105382. Epub 2023 Jan 26.
7
Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study.替沙格韦单抗和西加韦单抗（恩适得™）预防可防止免疫抑制人群出现突破性新冠病毒感染：6个月前瞻性研究
Vaccines (Basel). 2023 Feb 3;11(2):350. doi: 10.3390/vaccines11020350.
8
Tixagevimab-Cilgavimab: COVID-19 Pre-Exposure Prophylaxis.泰它西单抗-西加韦单抗：COVID-19 暴露前预防。
Clin J Oncol Nurs. 2022 Sep 15;26(5):479-482. doi: 10.1188/22.CJON.479-482.
9
Increased reporting of venous and arterial thromboembolic events reported with tixagevimab-cilgavimab for coronavirus disease 2019.与 COVID-19 相关的替沙格韦单抗-西加韦单抗静脉和动脉血栓栓塞事件报告增加。
Clin Microbiol Infect. 2023 Apr;29(4):543.e1-543.e3. doi: 10.1016/j.cmi.2022.11.026. Epub 2022 Dec 1.
10
Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections.接种替沙格韦单抗/西加韦单抗后对奥密克戎 BA.5 的中和活性与奥密克戎 BA.1/BA.2 突破性感染后的中和活性相当。
Front Immunol. 2023 Mar 2;14:1139980. doi: 10.3389/fimmu.2023.1139980. eCollection 2023.

本文引用的文献

1
T cell immunity to COVID-19 vaccines.T 细胞对 COVID-19 疫苗的免疫反应。
Science. 2022 Aug 19;377(6608):821-822. doi: 10.1126/science.add2897. Epub 2022 Aug 18.
2
Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.替沙格韦单抗和西加韦单抗（Evusheld）用于 1112 例严重免疫功能低下患者的 COVID-19 暴露前预防。
Clin Microbiol Infect. 2022 Dec;28(12):1654.e1-1654.e4. doi: 10.1016/j.cmi.2022.07.015. Epub 2022 Aug 1.
3
Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality.
AZD7442（替沙格韦单抗-西加韦单抗）给药与严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染、住院和死亡的关联。
Clin Infect Dis. 2023 Feb 8;76(3):e126-e132. doi: 10.1093/cid/ciac625.
4
Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis.接受替沙格韦单抗-西加韦单抗预防的免疫功能低下患者中早发性严重急性呼吸综合征冠状病毒2感染的特征
Open Forum Infect Dis. 2022 Jun 7;9(7):ofac283. doi: 10.1093/ofid/ofac283. eCollection 2022 Jul.
5
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.奥密克戎 BA.4 和 BA.5 对疫苗和 BA.1 血清的抗体逃逸。
Cell. 2022 Jul 7;185(14):2422-2433.e13. doi: 10.1016/j.cell.2022.06.005. Epub 2022 Jun 9.
6
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.AZD7442（替沙格韦单抗-西加韦单抗）对血液系统恶性肿瘤患者中奥密克戎SARS-CoV-2的活性。
Cancer Cell. 2022 Jun 13;40(6):590-591. doi: 10.1016/j.ccell.2022.05.007. Epub 2022 May 16.
7
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.肌肉注射 AZD7442（替沙格韦单抗-西加韦单抗）预防新冠病毒感染。
N Engl J Med. 2022 Jun 9;386(23):2188-2200. doi: 10.1056/NEJMoa2116620. Epub 2022 Apr 20.
8
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.布鲁顿酪氨酸激酶（BTK）抑制剂的心脏毒性：依鲁替尼及其他。
Expert Rev Hematol. 2022 Apr;15(4):321-331. doi: 10.1080/17474086.2022.2067526. Epub 2022 Apr 22.
9
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.成人血液恶性肿瘤患者接种 SARS-CoV-2 疫苗后的抗体反应：系统评价和荟萃分析。
Haematologica. 2022 Aug 1;107(8):1840-1849. doi: 10.3324/haematol.2021.280163.
10
Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively.将免疫功能恢复作为有效治疗慢性淋巴细胞白血病的补充策略。
J Exp Clin Cancer Res. 2021 Oct 15;40(1):321. doi: 10.1186/s13046-021-02115-1.